Visceral leishmaniasis infection during adalimumab therapy: A case report and literature review

International Journal of Rheumatic Diseases

Volumn 17, Issue 7, 2014, Pages 822-824

  Tung Chen, Yale ^a   Perales, Carolina ^a   Lacruz, Jose ^a   Senent, Leonor ^a   Salavert, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B LIPID COMPLEX; C REACTIVE PROTEIN; FERRITIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; AGED; AMASTIGOTE; ASTHENIA; BONE MARROW BIOPSY; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FERRITIN BLOOD LEVEL; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LEISHMANIA; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; VISCERAL LEISHMANIASIS; ARTHRITIS, RHEUMATOID; BONE MARROW EXAMINATION; CHEMICALLY INDUCED; DRUG SUBSTITUTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; PARASITOLOGY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

AGED; AMPHOTERICIN B; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPROTOZOAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE MARROW EXAMINATION; DRUG SUBSTITUTION; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; MALE; METHYLPREDNISOLONE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84938085192     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12427     Document Type: Letter

References (14)

1. Van Griensven J, Diro E (2012) Visceral leishmaniasis. Infect Dis Clin North Am 26, 309-22.
2. Ali T, Bronze MS, Kaitha S, Mahmood S, Ftaisi A, Stone J (2013) Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 5, 79-99.
3. De Leonardis F, Govoni M, Lo Monaco A, Trotta F (2009) Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature. Clin Exp Rheumatol 27, 503-6.
4. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C (2006) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 45, 1446-8.
5. Romero-Maté A, Martínez-Sánchez D, Tardío JC et al. (2012) Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab. Dermatol Online J 18, 7.
6. Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, Henrique da Mota LM, de Menezes I, Aaron Scheinberg M (2013) Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum 43, 152-7.
7. McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 64, 3129-38.
8. Zanger P, Kötter I, Kremsner PG, Gabrysch S (2012) Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe: anti-TNF therapy and leishmaniasis in Europe. Clin Microbiol Infect 18, 670-6.
9. Berry CE, Tsai J, Tierney A, Pickles R (2013) Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. Med J Aust 198, 331-3.
10. Moreno D, Martínez P, Berbegal J, Femenia M (2010) Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review. Enferm Infecc Microbiol Clín 28, 261-2.
11. Moltó A, Mateo L, Lloveras N, Olivé A, Minguez S (2010) Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 77, 271-3.
12. Erre GL, Mesina P, Tonelli N, Passiu G (2010) Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol 28, 590-1.
13. Khan A, Coakley G, Cosgrove C, Lockwood D (2010) Let off the leash: kala-azar following the use of tumour necrosis factor antibodies. BMJ Case Rep 2010, doi: 10.1136/bcr.04.2010.2878.
14. Pizzorni C, Secchi ME, Cutolo M (2011) Leishmaniasis in rheumatoid arthritis. Reumatismo 59, 235-9.